Nucleoside-modified RNA for inducing an immune response against zika virus
US11241490B2 · kind B2 · utility
2Cited by
9References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 11, 2018 |
| Grant date | Feb 8, 2022 |
| Priority date | — |
| Expiry date | Jan 11, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for inducing an adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.